patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_219235 | REC_0014601 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 6.9 | 68 | female | 1 | 22 | 5.2 | 7 | entrectinib 600 mg daily | 15.4 | false | MSS | 2026-03-15T05:36:00.861377+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_495947 | REC_0014602 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 5.8 | 75 | female | 2 | 22 | 6 | 2 | carboplatin + paclitaxel + pembrolizumab | 16 | false | MSS | 2026-03-15T05:36:00.861690+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_991420 | REC_0014603 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 5 | 70 | female | 0 | 17 | 3.5 | 2 | osimertinib 80 mg daily | 32.2 | true | MSS | 2026-03-15T05:36:00.862010+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_150317 | REC_0014604 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 24 | 10.8 | 70 | female | 0 | 18 | 6.1 | 0 | sotorasib 960 mg daily | 36.4 | false | MSS | 2026-03-15T05:36:00.862346+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_304947 | REC_0014605 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 18.2 | 75 | female | 1 | 8 | 5.7 | 6 | osimertinib 80 mg daily | 11.3 | false | MSI-H | 2026-03-15T05:36:00.862696+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_934960 | REC_0014606 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 17.1 | 68 | female | 1 | 28 | 4.4 | 4 | alectinib 600 mg BID | 10.3 | true | MSS | 2026-03-15T05:36:00.863068+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_944821 | REC_0014607 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 32 | 7.4 | 69 | female | 0 | 28 | 5.2 | 2 | carboplatin + paclitaxel + pembrolizumab | 7.1 | true | MSS | 2026-03-15T05:36:00.863365+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_542309 | REC_0014608 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 9.6 | 71 | female | 2 | 24 | 4.6 | 2 | osimertinib 80 mg daily | 12.1 | false | MSS | 2026-03-15T05:36:00.863717+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_223852 | REC_0014609 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 24 | 16.6 | 64 | female | 0 | 14 | 5.5 | 3 | pembrolizumab 200 mg q3w | 4.1 | true | MSI-H | 2026-03-15T05:36:00.864001+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_689313 | REC_0014610 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 24 | 5 | 71 | female | 1 | 70 | 4.6 | 2 | pembrolizumab 200 mg q3w | 16.8 | false | MSS | 2026-03-15T05:36:00.864347+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_161733 | REC_0014611 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 29 | 14.8 | 65 | male | 1 | 11 | 4.1 | 2 | pembrolizumab 200 mg q3w | 8.3 | false | MSI-H | 2026-03-15T05:36:00.864650+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_992721 | REC_0014612 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 14.2 | 67 | female | 0 | 21 | 5.1 | 4 | osimertinib 80 mg daily | 12.8 | true | MSI-H | 2026-03-15T05:36:00.864943+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_633533 | REC_0014613 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 8 | 52 | male | 0 | 9 | 5.1 | 4 | alectinib 600 mg BID | 10.6 | true | MSS | 2026-03-15T05:36:00.865371+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_370987 | REC_0014614 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 10.4 | 81 | male | 2 | 19 | 5.2 | 5 | osimertinib 80 mg daily | 13.9 | true | MSI-H | 2026-03-15T05:36:00.865700+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_635060 | REC_0014615 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 6.2 | 70 | female | 3 | 19 | 6.3 | 1 | sotorasib 960 mg daily | 31.1 | false | MSS | 2026-03-15T05:36:00.865991+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_173795 | REC_0014616 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 26 | 15.4 | 87 | female | 0 | 14 | 4.3 | 2 | osimertinib 80 mg daily | 18 | true | MSI-H | 2026-03-15T05:36:00.866274+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_300289 | REC_0014617 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 10.5 | 63 | male | 1 | 18 | 6.3 | 2 | osimertinib 80 mg daily | 11.8 | false | MSS | 2026-03-15T05:36:00.866562+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_440233 | REC_0014618 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 13.4 | 78 | female | 2 | 19 | 5.8 | 6 | alectinib 600 mg BID | 6.7 | true | MSS | 2026-03-15T05:36:00.866893+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_255810 | REC_0014619 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 11.5 | 59 | female | 1 | 30 | 4.1 | 4 | entrectinib 600 mg daily | 9.8 | true | MSI-H | 2026-03-15T05:36:00.867219+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_483217 | REC_0014620 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 20 | 12.3 | 60 | female | 1 | 16 | 5.6 | 2 | sotorasib 960 mg daily | 24.6 | false | MSI-H | 2026-03-15T05:36:00.867540+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_440798 | REC_0014621 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 6.7 | 68 | male | 1 | 9 | 2.9 | 5 | osimertinib 80 mg daily | 9.3 | true | MSS | 2026-03-15T05:36:00.867852+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_152740 | REC_0014622 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 13 | 71 | female | 1 | 16 | 5.8 | 6 | entrectinib 600 mg daily | 9.3 | true | MSS | 2026-03-15T05:36:00.868241+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_400933 | REC_0014623 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 18 | 6 | 67 | female | 1 | 14 | 5.5 | 1 | pembrolizumab 200 mg q3w | 25.8 | false | MSS | 2026-03-15T05:36:00.868605+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_494143 | REC_0014624 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 35 | 8.2 | 71 | male | 1 | 11 | 4.3 | 1 | alectinib 600 mg BID | 13.3 | false | MSS | 2026-03-15T05:36:00.868905+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_476100 | REC_0014625 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 10 | 75 | female | 2 | 6 | 5.5 | 5 | entrectinib 600 mg daily | 14.4 | false | MSS | 2026-03-15T05:36:00.869212+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_591989 | REC_0014626 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 12 | 63 | male | 1 | 14 | 5.8 | 2 | alectinib 600 mg BID | 14.4 | true | MSI-H | 2026-03-15T05:36:00.869741+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_277301 | REC_0014627 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 12.9 | 85 | male | 1 | 17 | 6.4 | 7 | sotorasib 960 mg daily | 12.5 | false | MSI-H | 2026-03-15T05:36:00.870088+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_172184 | REC_0014628 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 7.5 | 70 | male | 2 | 24 | 4.9 | 10 | carboplatin + paclitaxel + pembrolizumab | 8.4 | true | MSS | 2026-03-15T05:36:00.870405+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_855877 | REC_0014629 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 16.5 | 71 | female | 1 | 4 | 7 | 7 | entrectinib 600 mg daily | 14.3 | false | MSS | 2026-03-15T05:36:00.870741+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_479504 | REC_0014630 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 20 | 12 | 54 | female | 0 | 18 | 6.4 | 7 | pembrolizumab 200 mg q3w | 7.4 | false | MSI-H | 2026-03-15T05:36:00.871065+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_349262 | REC_0014631 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 25 | 13.1 | 74 | female | 3 | 0 | 5.3 | 0 | osimertinib 80 mg daily | 39.5 | false | MSS | 2026-03-15T05:36:00.871377+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_606916 | REC_0014632 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 6.2 | 61 | male | 1 | 55 | 5.6 | 4 | carboplatin + paclitaxel + pembrolizumab | 10.4 | false | MSS | 2026-03-15T05:36:00.871679+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_930020 | REC_0014633 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 14.4 | 81 | female | 2 | 15 | 7.3 | 5 | alectinib 600 mg BID | 7.4 | true | MSS | 2026-03-15T05:36:00.871957+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_527974 | REC_0014634 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 16.7 | 62 | male | 0 | 12 | 7.3 | 2 | osimertinib 80 mg daily | 21 | false | MSI-H | 2026-03-15T05:36:00.872338+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_905975 | REC_0014635 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 16.3 | 68 | male | 1 | 15 | 5.8 | 5 | osimertinib 80 mg daily | 11.6 | false | MSI-H | 2026-03-15T05:36:00.872680+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_622715 | REC_0014636 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 11.1 | 64 | female | 0 | 14 | 5.8 | 6 | sotorasib 960 mg daily | 13 | false | MSS | 2026-03-15T05:36:00.873001+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_954733 | REC_0014637 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 32 | 4.9 | 66 | female | 1 | 16 | 6.2 | 1 | entrectinib 600 mg daily | 25.6 | false | MSS | 2026-03-15T05:36:00.873334+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_443182 | REC_0014638 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 11.6 | 53 | female | 0 | 22 | 6.4 | 4 | alectinib 600 mg BID | 10.5 | true | MSS | 2026-03-15T05:36:00.873675+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_919978 | REC_0014639 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 11.3 | 69 | female | 0 | 2 | 7 | 7 | osimertinib 80 mg daily | 19.4 | false | MSS | 2026-03-15T05:36:00.874161+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_545413 | REC_0014640 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 13.5 | 58 | female | 0 | 25 | 6 | 2 | sotorasib 960 mg daily | 19.6 | false | MSI-H | 2026-03-15T05:36:00.874535+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_730523 | REC_0014641 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 11.7 | 51 | male | 0 | 13 | 5.9 | 6 | entrectinib 600 mg daily | 8 | true | MSI-H | 2026-03-15T05:36:00.874864+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_897319 | REC_0014642 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 10.1 | 75 | female | 1 | 12 | 6.9 | 4 | osimertinib 80 mg daily | 16.1 | true | MSS | 2026-03-15T05:36:00.875178+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_320281 | REC_0014643 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 11.1 | 62 | male | 1 | 18 | 5.6 | 6 | entrectinib 600 mg daily | 14.9 | false | MSI-H | 2026-03-15T05:36:00.875513+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_401804 | REC_0014644 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 28 | 5.3 | 77 | female | 2 | 21 | 4.7 | 3 | pembrolizumab 200 mg q3w | 8.8 | false | MSS | 2026-03-15T05:36:00.875851+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_165820 | REC_0014645 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 5.4 | 75 | female | 3 | 13 | 4.8 | 2 | osimertinib 80 mg daily | 19.9 | false | MSS | 2026-03-15T05:36:00.876257+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_229681 | REC_0014646 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 25 | 7.1 | 60 | male | 1 | 18 | 6.9 | 6 | pembrolizumab 200 mg q3w | 15.4 | true | MSS | 2026-03-15T05:36:00.876613+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_881670 | REC_0014647 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 17.2 | 68 | female | 1 | 11 | 5.1 | 4 | alectinib 600 mg BID | 6.3 | false | MSI-H | 2026-03-15T05:36:00.876968+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_896515 | REC_0014648 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 19 | 2.9 | 66 | female | 1 | 49 | 6.2 | 2 | carboplatin + paclitaxel + pembrolizumab | 13.7 | false | MSS | 2026-03-15T05:36:00.877319+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_893902 | REC_0014649 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 11.3 | 78 | male | 2 | 22 | 4.2 | 7 | alectinib 600 mg BID | 9.6 | true | MSI-H | 2026-03-15T05:36:00.877660+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_833462 | REC_0014650 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 35 | 10.4 | 74 | female | 2 | 11 | 6.5 | 2 | entrectinib 600 mg daily | 21.5 | true | MSS | 2026-03-15T05:36:00.877990+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_577494 | REC_0014651 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 15 | 16.1 | 79 | female | 0 | 9 | 7.2 | 7 | sotorasib 960 mg daily | 11.1 | true | MSI-H | 2026-03-15T05:36:00.878321+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_413366 | REC_0014652 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 13.9 | 64 | male | 1 | 18 | 3.2 | 7 | entrectinib 600 mg daily | 5.3 | true | MSS | 2026-03-15T05:36:00.878805+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_490446 | REC_0014653 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 23 | 8.4 | 47 | female | 0 | 22 | 7.1 | 7 | pembrolizumab 200 mg q3w | 12.9 | true | MSS | 2026-03-15T05:36:00.879172+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_594805 | REC_0014654 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 11.3 | 88 | female | 1 | 12 | 4.8 | 8 | alectinib 600 mg BID | 9.6 | false | MSI-H | 2026-03-15T05:36:00.879549+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_238255 | REC_0014655 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 6.4 | 76 | female | 2 | 7 | 6 | 6 | alectinib 600 mg BID | 6.3 | true | MSS | 2026-03-15T05:36:00.879895+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_268100 | REC_0014656 | Non-small cell lung cancer | Large cell carcinoma | III | None (PD-L1 high) | 16 | 6.8 | 63 | female | 0 | 23 | 4.8 | 0 | pembrolizumab 200 mg q3w | 41.8 | true | MSS | 2026-03-15T05:36:00.880315+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_544717 | REC_0014657 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 31 | 10.5 | 67 | female | 1 | 10 | 5.7 | 3 | alectinib 600 mg BID | 4.2 | false | MSI-H | 2026-03-15T05:36:00.880669+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_610989 | REC_0014658 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 6.2 | 75 | female | 1 | 54 | 4.5 | 2 | carboplatin + paclitaxel + pembrolizumab | 13 | true | MSS | 2026-03-15T05:36:00.880996+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_373878 | REC_0014659 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 11.8 | 68 | female | 1 | 8 | 4.9 | 1 | sotorasib 960 mg daily | 27.2 | true | MSS | 2026-03-15T05:36:00.881345+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_184572 | REC_0014660 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 21 | 12.3 | 61 | female | 0 | 4 | 7 | 0 | osimertinib 80 mg daily | 43.8 | true | MSS | 2026-03-15T05:36:00.881683+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_711344 | REC_0014661 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 23 | 5.5 | 71 | female | 1 | 19 | 6.4 | 1 | pembrolizumab 200 mg q3w | 9.6 | false | MSS | 2026-03-15T05:36:00.882003+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_610698 | REC_0014662 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 19 | 13.8 | 71 | female | 1 | 14 | 6.3 | 1 | osimertinib 80 mg daily | 13.5 | true | MSS | 2026-03-15T05:36:00.882317+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_216519 | REC_0014663 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 7.5 | 61 | female | 1 | 13 | 3 | 4 | osimertinib 80 mg daily | 8.9 | true | MSS | 2026-03-15T05:36:00.882624+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_631367 | REC_0014664 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 13.5 | 77 | female | 1 | 7 | 4.9 | 9 | entrectinib 600 mg daily | 11.5 | false | MSI-H | 2026-03-15T05:36:00.882906+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_214903 | REC_0014665 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 16 | 14.1 | 70 | female | 3 | 22 | 5.5 | 6 | osimertinib 80 mg daily | 9.9 | true | MSS | 2026-03-15T05:36:00.883281+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_364647 | REC_0014666 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 5.1 | 55 | female | 0 | 13 | 3.8 | 5 | carboplatin + paclitaxel + pembrolizumab | 5.8 | true | MSS | 2026-03-15T05:36:00.883536+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_880458 | REC_0014667 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 11.1 | 71 | female | 3 | 9 | 6.3 | 1 | osimertinib 80 mg daily | 20.8 | false | MSS | 2026-03-15T05:36:00.883818+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_748313 | REC_0014668 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 27 | 11.2 | 63 | male | 0 | 12 | 4.5 | 1 | sotorasib 960 mg daily | 16.8 | false | MSI-H | 2026-03-15T05:36:00.884157+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_871474 | REC_0014669 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 10 | 76 | male | 2 | 5 | 5.3 | 9 | alectinib 600 mg BID | 13 | true | MSI-H | 2026-03-15T05:36:00.884467+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_527943 | REC_0014670 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 11.1 | 61 | male | 1 | 24 | 5.7 | 2 | sotorasib 960 mg daily | 7.7 | true | MSI-H | 2026-03-15T05:36:00.884775+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_773725 | REC_0014671 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 12.9 | 72 | male | 0 | 14 | 4.1 | 1 | alectinib 600 mg BID | 6.6 | true | MSI-H | 2026-03-15T05:36:00.885063+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_132750 | REC_0014672 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 19.1 | 71 | female | 1 | 16 | 3.4 | 6 | sotorasib 960 mg daily | 19 | true | MSS | 2026-03-15T05:36:00.885314+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_847360 | REC_0014673 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 4.2 | 57 | male | 1 | 26 | 5.3 | 1 | osimertinib 80 mg daily | 19.1 | false | MSS | 2026-03-15T05:36:00.885559+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_972674 | REC_0014674 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 6.9 | 70 | female | 2 | 66 | 6.2 | 4 | carboplatin + paclitaxel + pembrolizumab | 11 | false | MSS | 2026-03-15T05:36:00.885798+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_757132 | REC_0014675 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 21 | 6.5 | 53 | female | 0 | 15 | 5.4 | 4 | pembrolizumab 200 mg q3w | 7 | true | MSS | 2026-03-15T05:36:00.886036+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_289780 | REC_0014676 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 6.1 | 72 | male | 1 | 89 | 3.4 | 1 | carboplatin + paclitaxel + pembrolizumab | 24.9 | false | MSS | 2026-03-15T05:36:00.886291+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_312858 | REC_0014677 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 9.8 | 56 | female | 0 | 12 | 6.1 | 8 | entrectinib 600 mg daily | 11.6 | false | MSS | 2026-03-15T05:36:00.886588+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_786564 | REC_0014678 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 4.3 | 66 | female | 0 | 51 | 6.5 | 6 | carboplatin + paclitaxel + pembrolizumab | 6.5 | true | MSS | 2026-03-15T05:36:00.886980+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_547194 | REC_0014679 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 12.8 | 63 | female | 1 | 17 | 3.8 | 4 | alectinib 600 mg BID | 10.8 | false | MSI-H | 2026-03-15T05:36:00.887257+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_510309 | REC_0014680 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 32 | 11.2 | 68 | female | 0 | 10 | 3.8 | 4 | sotorasib 960 mg daily | 16.4 | false | MSS | 2026-03-15T05:36:00.887533+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_451806 | REC_0014681 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 15.3 | 65 | male | 0 | 17 | 4.7 | 5 | entrectinib 600 mg daily | 8.3 | true | MSS | 2026-03-15T05:36:00.887789+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_757496 | REC_0014682 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 8.4 | 70 | female | 1 | 61 | 6.3 | 2 | carboplatin + paclitaxel + pembrolizumab | 8 | false | MSS | 2026-03-15T05:36:00.888046+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_650255 | REC_0014683 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 22 | 7.1 | 45 | female | 0 | 15 | 4 | 6 | pembrolizumab 200 mg q3w | 12.4 | false | MSS | 2026-03-15T05:36:00.888387+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_194860 | REC_0014684 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 30 | 9.3 | 68 | male | 1 | 65 | 4.8 | 1 | carboplatin + paclitaxel + pembrolizumab | 12.7 | true | MSS | 2026-03-15T05:36:00.888665+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_686933 | REC_0014685 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 27 | 8 | 77 | female | 2 | 48 | 4.9 | 6 | pembrolizumab 200 mg q3w | 9.2 | true | MSS | 2026-03-15T05:36:00.888916+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_924941 | REC_0014686 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 7 | 69 | female | 0 | 15 | 5.8 | 4 | osimertinib 80 mg daily | 12.1 | true | MSS | 2026-03-15T05:36:00.889170+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_601059 | REC_0014687 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 11.9 | 85 | female | 0 | 16 | 5.5 | 1 | alectinib 600 mg BID | 18 | true | MSI-H | 2026-03-15T05:36:00.889429+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_139803 | REC_0014688 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 19 | 5 | 72 | female | 1 | 29 | 5.8 | 1 | entrectinib 600 mg daily | 19.1 | false | MSS | 2026-03-15T05:36:00.889682+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_204594 | REC_0014689 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 20 | 7.4 | 75 | female | 2 | 13 | 7 | 1 | alectinib 600 mg BID | 31.5 | false | MSS | 2026-03-15T05:36:00.889927+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_137913 | REC_0014690 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 18 | 13.1 | 74 | female | 2 | 15 | 4.6 | 1 | entrectinib 600 mg daily | 18.7 | false | MSI-H | 2026-03-15T05:36:00.890182+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_532927 | REC_0014691 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 34 | 12 | 73 | female | 1 | 14 | 5.8 | 5 | entrectinib 600 mg daily | 5.8 | true | MSI-H | 2026-03-15T05:36:00.890578+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_841001 | REC_0014692 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 31 | 11.2 | 72 | female | 2 | 25 | 3.8 | 2 | sotorasib 960 mg daily | 25.1 | false | MSS | 2026-03-15T05:36:00.890861+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_116759 | REC_0014693 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 13.2 | 63 | male | 0 | 14 | 4.8 | 1 | osimertinib 80 mg daily | 8.5 | false | MSS | 2026-03-15T05:36:00.891140+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_171566 | REC_0014694 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 13.7 | 68 | female | 1 | 19 | 5.8 | 6 | sotorasib 960 mg daily | 11.6 | true | MSS | 2026-03-15T05:36:00.891412+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_566197 | REC_0014695 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 9 | 52 | female | 0 | 13 | 4.1 | 1 | osimertinib 80 mg daily | 28.2 | false | MSS | 2026-03-15T05:36:00.891690+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_748480 | REC_0014696 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 11 | 62 | female | 0 | 10 | 7.3 | 8 | entrectinib 600 mg daily | 16.3 | false | MSI-H | 2026-03-15T05:36:00.891959+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_695403 | REC_0014697 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 25 | 7.7 | 79 | female | 4 | 72 | 5.2 | 4 | pembrolizumab 200 mg q3w | 11.2 | false | MSS | 2026-03-15T05:36:00.892288+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_300924 | REC_0014698 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 28 | 13.5 | 74 | female | 0 | 14 | 6 | 1 | osimertinib 80 mg daily | 25.8 | true | MSS | 2026-03-15T05:36:00.892563+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_215395 | REC_0014699 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 10.9 | 72 | female | 1 | 27 | 5.3 | 4 | sotorasib 960 mg daily | 12.7 | true | MSI-H | 2026-03-15T05:36:00.892833+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_750422 | REC_0014700 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 6.7 | 82 | female | 2 | 46 | 6.1 | 4 | carboplatin + paclitaxel + pembrolizumab | 12.5 | false | MSS | 2026-03-15T05:36:00.893085+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.